Search results
Kapitalo Investimentos Ltda Purchases 130 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 17 hours agoKapitalo Investimentos Ltda increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 118.2% in the fourth ...
Regeneron holds Buy rating and price target from TD Cowen By Investing.com
Investing.com· 5 days agoOn Friday, TD Cowen maintained a Buy rating on shares of Regeneron (NASDAQ:REGN) Pharmaceuticals (...
Regeneron director Brown sells shares worth over $1.5 million By Investing.com
Investing.com· 2 days agoRegeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) Director Michael S. Brown has completed...
Insider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Sells 9,064 Shares of Stock
ETF DAILY NEWS· 6 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) CEO Leonard S. Schleifer sold 9,064 shares of the company’s stock in ...
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 52-Week High Following Analyst Upgrade
ETF DAILY NEWS· 3 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week high during mid-day trading on Monday after ...
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past...
Simply Wall St. via Yahoo Finance· 6 days agoBut on a lighter note, a good company can see its share price rise well over 100%. Long term ...
Regeneron CEO Leonard Schleifer sells over $25 million in company stock By Investing.com
Investing.com· 6 days agoRegeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) has reported a series of transactions by...
...Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN - ...
Benzinga· 5 days agoNEW YORK, June 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron ...
...Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market - Regeneron ...
Benzinga· 6 days agoAnalyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.
Equities Research Analysts’ Price Target Changes for June 17th (ACN, AMAT, AMH, ARM, ASML, AVB,...
ETF DAILY NEWS· 2 days agoEquities Research Analysts’ price target changes for Monday, June 17th: Accenture (NYSE:ACN) had its...